Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Macule23.03.03.0370.002780%Not Available
Malaise08.01.01.003--
Memory impairment17.03.02.003; 19.20.01.003--
Menstrual disorder21.01.01.004--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Metabolic acidosis14.01.01.0030.052815%Not Available
Microcytic anaemia01.03.02.0080.002780%Not Available
Movement disorder17.01.02.0100.002780%Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.0080.002780%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.011119%
Mydriasis17.02.11.003; 06.05.03.0040.002780%Not Available
Nausea07.01.07.001--
Nephrolithiasis20.04.01.0020.004170%
Nephrotic syndrome20.05.01.0020.006949%
Nervousness19.06.02.003--Not Available
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.0030.022516%Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.011119%Not Available
Nicotinic acid deficiency23.03.04.013; 14.12.02.0020.006115%Not Available
Nocturia20.02.03.001--Not Available
Obsessive-compulsive disorder19.06.05.0020.002780%Not Available
Oedema14.05.06.010; 08.01.07.0060.005560%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.013065%
Oliguria20.01.03.0040.005560%Not Available
Optic neuritis06.04.08.002; 10.02.01.097; 17.04.05.0010.004170%Not Available
Oral pain07.05.05.034--
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.005560%Not Available
Pancreatitis07.18.01.0010.005560%
Pancreatitis acute07.18.01.0020.027798%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene